{"id":5040,"date":"2024-11-28T13:05:32","date_gmt":"2024-11-28T07:35:32","guid":{"rendered":"https:\/\/eliteayurveda.com\/blog\/?p=5040"},"modified":"2024-11-28T13:05:37","modified_gmt":"2024-11-28T07:35:37","slug":"why-conventional-psoriasis-treatments-fail-and-the-path-to-true-healing","status":"publish","type":"post","link":"https:\/\/eliteayurveda.com\/blog\/why-conventional-psoriasis-treatments-fail-and-the-path-to-true-healing\/","title":{"rendered":"Why Conventional Psoriasis Treatments Fail\u2014and the Path to True Healing"},"content":{"rendered":"\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"whats-the-deal-with-my-psoriasis-treatment-why-cant-i-come-out-of-psoriasis\"><strong>What\u2019s the Deal with My Psoriasis Treatment? Why Can\u2019t I Come Out of Psoriasis?<\/strong><\/h3>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>Table of Contents<\/h2><nav><ul><li><a href=\"#whats-the-deal-with-my-psoriasis-treatment-why-cant-i-come-out-of-psoriasis\">What\u2019s the Deal with My Psoriasis Treatment? Why Can\u2019t I Come Out of Psoriasis?<\/a><\/li><li><a href=\"#why-allopathic-treatments-for-psoriasis-often-fail\">Why Allopathic Treatments for Psoriasis Often Fail<\/a><ul><li><a href=\"#1-drug-tolerance-tachyphylaxis\">1. Drug Tolerance (Tachyphylaxis)<\/a><\/li><li><a href=\"#2-toxicity-accumulation\">2. Toxicity Accumulation<\/a><\/li><li><a href=\"#3-development-of-anti-drug-antibodies-ad-as\">3. Development of Anti-Drug Antibodies (ADAs)<\/a><\/li><li><a href=\"#4-misdiagnosis-or-incomplete-diagnosis\">4. Misdiagnosis or Incomplete Diagnosis<\/a><\/li><li><a href=\"#5-psychological-and-financial-barriers\">5. Psychological and Financial Barriers<\/a><\/li><\/ul><\/li><li><a href=\"#the-difference-between-control-and-reversal-in-psoriasis-treatment\">The Difference Between Control and Reversal in Psoriasis Treatment<\/a><ul><li><a href=\"#control-centric-approach\">Control-Centric Approach<\/a><\/li><li><a href=\"#reversal-centric-approach\">Reversal-Centric Approach<\/a><\/li><\/ul><\/li><li><a href=\"#common-reasons-patients-struggle-with-psoriasis-reversal\">Common Reasons Patients Struggle with Psoriasis Reversal<\/a><\/li><li><a href=\"#our-approach-at-elite-ayurveda\">Our Approach at EliteAyurveda<\/a><ul><li><a href=\"#personalized-root-cause-treatment\">Personalized Root-Cause Treatment<\/a><\/li><li><a href=\"#key-elements-of-our-treatment\">Key Elements of Our Treatment<\/a><\/li><\/ul><\/li><li><a href=\"#case-study-breaking-free-from-psoriasis\">Case Study: Breaking Free from Psoriasis<\/a><\/li><li><a href=\"#from-the-doctors-desk-why-choose-ayurveda\">From the Doctor\u2019s Desk: Why Choose Ayurveda?<\/a><\/li><li><a href=\"#takeaway\">Takeaway<\/a><\/li><li><a href=\"#references\">References<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<p><strong>Estimated Reading Time: 10 Minutes<\/strong><\/p>\n\n\n\n<p>Psoriasis is a chronic autoimmune skin condition that manifests in several forms, each with varying severity and requiring individualized treatment (Langley, Krueger, &amp; Griffiths, 2005; Parisi et al., 2013). Its unpredictable nature, coupled with the inadequacies of conventional treatments, often leaves patients stuck in cycles of flare-ups and temporary relief (Feldman et al., 2008). This is not due to a lack of effort but rather a failure to address the root cause of the disease (Upadhyay, 2010).<\/p>\n\n\n\n<p>At <strong>EliteAyurveda<\/strong>, we meet many patients frustrated with their conventional treatments. By focusing on personalized Ayurvedic solutions, we help them break free from this cycle and move toward sustained remission (Singh, 2010).<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"770\" height=\"403\" src=\"https:\/\/eliteayurveda.com\/blog\/wp-content\/uploads\/2024\/11\/Ayurvedic-Approach-to-PSORIASIS.jpg\" alt=\"Why Conventional Psoriasis Treatments Fail\" class=\"wp-image-5043\" srcset=\"https:\/\/eliteayurveda.com\/blog\/wp-content\/uploads\/2024\/11\/Ayurvedic-Approach-to-PSORIASIS.jpg 770w, https:\/\/eliteayurveda.com\/blog\/wp-content\/uploads\/2024\/11\/Ayurvedic-Approach-to-PSORIASIS-300x157.jpg 300w, https:\/\/eliteayurveda.com\/blog\/wp-content\/uploads\/2024\/11\/Ayurvedic-Approach-to-PSORIASIS-768x402.jpg 768w, https:\/\/eliteayurveda.com\/blog\/wp-content\/uploads\/2024\/11\/Ayurvedic-Approach-to-PSORIASIS-696x364.jpg 696w\" sizes=\"auto, (max-width: 770px) 100vw, 770px\" \/><figcaption class=\"wp-element-caption\">Why Conventional Psoriasis Treatments Fail <\/figcaption><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"why-allopathic-treatments-for-psoriasis-often-fail\"><strong>Why Allopathic Treatments for Psoriasis Often Fail<\/strong><\/h3>\n\n\n\n<p>There are several reasons why conventional treatments lose their efficacy or fail entirely (Koo &amp; Lebwohl, 1999):<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"1-drug-tolerance-tachyphylaxis\"><strong>1. Drug Tolerance (Tachyphylaxis)<\/strong><\/h4>\n\n\n\n<p>Conventional treatments such as corticosteroids and non-steroidal topical therapies often lose effectiveness with prolonged use. This phenomenon, known as tachyphylaxis, occurs because the body develops a resistance to the treatment (Koo &amp; Lebwohl, 1999).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Example:<\/strong> A patient using topical steroids may find that after a few months, their blisters and plaques no longer respond as they once did. This leads to frustration and the need for stronger medications, increasing the risk of side effects (Feldman et al., 2008).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"2-toxicity-accumulation\"><strong>2. Toxicity Accumulation<\/strong><\/h4>\n\n\n\n<p>Systemic medications like methotrexate or cyclosporine, while effective initially, often result in toxic buildup in vital organs over time (Menter et al., 2019). Similarly, prolonged phototherapy is linked to an increased risk of skin cancer (Menter et al., 2019).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Real Case:<\/strong> A 40-year-old female patient came to us after developing liver toxicity from methotrexate use over 8 years. Though her psoriasis was temporarily managed, the severe side effects forced her to discontinue the treatment.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"3-development-of-anti-drug-antibodies-ad-as\"><strong>3. Development of Anti-Drug Antibodies (ADAs)<\/strong><\/h4>\n\n\n\n<p>When using biologic therapies, the body may develop anti-drug antibodies, reducing the efficacy of these treatments. This leads to what is known as <strong>biologic fatigue<\/strong>, where medications that once provided relief no longer work (Dommasch et al., 2018).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Observation:<\/strong> In our clinic, we frequently see patients who initially experienced remarkable improvement with biologics but later faced diminishing results and relapses within 6 months to a year (Dommasch et al., 2018).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"4-misdiagnosis-or-incomplete-diagnosis\"><strong>4. Misdiagnosis or Incomplete Diagnosis<\/strong><\/h4>\n\n\n\n<p>Psoriasis can sometimes be misdiagnosed as eczema or contact dermatitis. Without a correct diagnosis, patients may be subjected to inappropriate treatments that worsen their condition (Nair, 2018).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Example:<\/strong> A male patient, initially treated for fungal dermatitis, visited us after a year of worsening symptoms, which were later correctly identified as guttate psoriasis.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"5-psychological-and-financial-barriers\"><strong>5. Psychological and Financial Barriers<\/strong><\/h4>\n\n\n\n<p>The high costs of biologic drugs make them inaccessible to many, while the psychological toll of managing a chronic illness can lead to missed doses or inconsistent treatment (National Psoriasis Foundation, n.d.). Stress, a known trigger for psoriasis flare-ups, further exacerbates the condition (Feldman et al., 2008).<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"the-difference-between-control-and-reversal-in-psoriasis-treatment\"><strong>The Difference Between Control and Reversal in Psoriasis Treatment<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"control-centric-approach\"><strong>Control-Centric Approach<\/strong><\/h4>\n\n\n\n<p>In conventional medicine, psoriasis treatment is often focused on managing symptoms\u2014reducing redness, scaling, and inflammation through medications or phototherapy (Menter et al., 2019). While these measures provide temporary relief, they fail to address the deeper imbalances causing the condition (Upadhyay, 2010).<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Outcome:<\/strong> Patients may experience periods of remission but are often reliant on lifelong medications with mounting side effects (Koo &amp; Lebwohl, 1999).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"reversal-centric-approach\"><strong>Reversal-Centric Approach<\/strong><\/h4>\n\n\n\n<p>At <strong>EliteAyurveda<\/strong>, we focus on <strong>true reversal<\/strong>, which involves:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Identifying and addressing the root causes of psoriasis (Singh, 2010).<\/li>\n\n\n\n<li>Balancing the body\u2019s systems, including digestion, immunity, and detoxification pathways (Upadhyay, 2010).<\/li>\n\n\n\n<li>Reducing reliance on external medications by empowering the body to heal itself (Nair, 2018).<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"common-reasons-patients-struggle-with-psoriasis-reversal\"><strong>Common Reasons Patients Struggle with Psoriasis Reversal<\/strong><\/h3>\n\n\n\n<p>Here are some of the challenges patients face before switching to Ayurveda (Nair, 2018):<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Incomplete Remission:<\/strong> Conventional medications suppress symptoms but do not prevent flare-ups (Koo &amp; Lebwohl, 1999).<\/li>\n\n\n\n<li><strong>Overlapping Conditions:<\/strong> Comorbidities like diabetes, heart disease, or depression complicate treatment plans (Parisi et al., 2013).<\/li>\n\n\n\n<li><strong>Impatience with Long-Term Plans:<\/strong> Biologic therapies often take months to show results, and even then, they may not deliver complete relief (Dommasch et al., 2018).<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"our-approach-at-elite-ayurveda\"><strong>Our Approach at EliteAyurveda<\/strong><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"personalized-root-cause-treatment\"><strong>Personalized Root-Cause Treatment<\/strong><\/h4>\n\n\n\n<p>Unlike generic treatments, we develop individualized plans based on each patient\u2019s unique constitution (<strong>Prakriti<\/strong>) and specific imbalances (Singh, 2010).<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"key-elements-of-our-treatment\"><strong>Key Elements of Our Treatment<\/strong><\/h4>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Detoxification (Shodhana):<\/strong>\n<ul class=\"wp-block-list\">\n<li>Specialized external Ayurvedic therapies to eliminate toxins (<strong>Ama<\/strong>) and reduce inflammation (Upadhyay, 2010).<\/li>\n\n\n\n<li>Gentle internal detox protocols to cleanse the liver and blood (Nair, 2018).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Personalized Herbal Medications:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Tailored herbal formulations to pacify aggravated <strong>Pitta<\/strong> and strengthen the immune system (Upadhyay, 2010).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Dietary Guidance:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Cooling foods like coconut water and cucumber to calm inflammation (Singh, 2010).<\/li>\n\n\n\n<li>Avoidance of Pitta-aggravating foods such as spicy and processed items (Nair, 2018).<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Lifestyle Adjustments:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Stress management through yoga and meditation (Singh, 2010).<\/li>\n\n\n\n<li>Daily routines to restore circadian rhythms and stabilize immunity (Upadhyay, 2010).<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"case-study-breaking-free-from-psoriasis\"><strong>Case Study: Breaking Free from Psoriasis<\/strong><\/h3>\n\n\n\n<p><strong>Patient Profile:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Name:<\/strong> Mr. Suresh (Name Changed)<\/li>\n\n\n\n<li><strong>Age:<\/strong> 35<\/li>\n\n\n\n<li><strong>Symptoms:<\/strong> Scaly patches covering 40% of his body, severe itching, and joint pain.<\/li>\n\n\n\n<li><strong>Previous Treatment:<\/strong> Biologics for 5 years with diminishing returns and new side effects, including chronic fatigue (Dommasch et al., 2018).<\/li>\n<\/ul>\n\n\n\n<p><strong>Ayurvedic Treatment Plan:<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Detoxification:<\/strong> Weekly specialized therapies to cleanse the liver and eliminate toxins (Upadhyay, 2010).<\/li>\n\n\n\n<li><strong>Herbal Support:<\/strong> Personalized medications to balance Pitta and support skin healing (Singh, 2010).<\/li>\n\n\n\n<li><strong>Dietary Adjustments:<\/strong> Pitta-pacifying diet with cooling foods and hydration-focused meals (Nair, 2018).<\/li>\n\n\n\n<li><strong>Stress Reduction:<\/strong> Pranayama and guided meditation for emotional balance (Singh, 2010).<\/li>\n<\/ol>\n\n\n\n<p><strong>Outcome:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Within 2 months: Reduced scaling and itching by 60%.<\/li>\n\n\n\n<li>Within 6 months: Clear skin and improved joint mobility.<\/li>\n\n\n\n<li>Sustained remission for 3 years with no dependence on biologics.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"from-the-doctors-desk-why-choose-ayurveda\"><strong>From the Doctor\u2019s Desk: Why Choose Ayurveda?<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sustainable Healing:<\/strong> True psoriasis reversal is possible by addressing its root causes (Upadhyay, 2010).<\/li>\n\n\n\n<li><strong>Fewer Side Effects:<\/strong> Herbal medications offer relief without the toxicity of systemic drugs (Nair, 2018).<\/li>\n\n\n\n<li><strong>Holistic Care:<\/strong> We focus on the whole body, not just the skin (Singh, 2010).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"takeaway\"><strong>Takeaway<\/strong><\/h3>\n\n\n\n<p>Psoriasis is a complex condition requiring more than symptomatic control. While conventional treatments often focus on managing flare-ups, they fail to address the underlying causes, leaving patients in a cycle of dependency and relapse (Koo &amp; Lebwohl, 1999). Ayurveda provides a path to true healing by addressing the root causes and restoring balance to the body (Upadhyay, 2010).<\/p>\n\n\n\n<p>At <strong>EliteAyurveda<\/strong>, we specialize in empowering patients with natural, personalized treatments for sustained relief and improved quality of life.<\/p>\n\n\n\n<p><strong>Take the first step toward psoriasis reversal today.<\/strong><br>\ud83d\udcde <strong>Contact us at +91 8884722246<\/strong><br>\ud83c\udf10 <strong>Visit our website: <a href=\"https:\/\/www.eliteayurveda.com\/\">www.eliteayurveda.com<\/a><\/strong><\/p>\n\n\n\n<p><strong>Related-<\/strong><\/p>\n\n\n\n<p><a href=\"https:\/\/www.eliteayurveda.com\/diseases\/skin\/psoriasis\/\" target=\"_blank\" rel=\"noreferrer noopener\">Know More About Ayurveda Treatment For Psoriasis<\/a><\/p>\n\n\n\n<div class=\"wp-block-group alignfull has-text-color has-background\" style=\"color:#000000;background-color:#ffffff\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center has-small-font-size\" style=\"line-height:.9\"><strong>GET IN TOUCH<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading has-text-align-center\" id=\"schedule-a-visit\" style=\"font-size:59px;line-height:1.15\"><strong><a href=\"https:\/\/www.eliteayurveda.com\/contact-us\/\" target=\"_blank\" rel=\"noreferrer noopener\">Schedule a Visit<\/a><\/strong><\/h2>\n\n\n\n<div class=\"wp-block-buttons is-horizontal is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-499968f5 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-50\"><a class=\"wp-block-button__link has-text-color has-background wp-element-button\" href=\"https:\/\/www.eliteayurveda.com\/contact-us\/\" style=\"border-radius:50px;color:#ffffff;background-color:#000000\" target=\"_blank\" rel=\"noreferrer noopener\">Contact us<\/a><\/div>\n<\/div>\n\n\n\n<div style=\"height:64px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<\/div><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"references\"><strong>References<\/strong><\/h3>\n\n\n\n<p>1.World Health O. Global Report on Psoriasis. World Health Organization; Geneva, Switzerland: 2016.\u00a0[<a href=\"https:\/\/scholar.google.com\/scholar_lookup?title=Global%20Report%20on%20Psoriasis&amp;author=O.%20World%20Health&amp;publication_year=2016&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>2.Griffiths C.E.M., Armstrong A.W., Gudjonsson J.E., Barker J. Psoriasis. Lancet. 2021;397:1301\u20131315. doi: 10.1016\/S0140-6736(20)32549-6.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33812489\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Lancet&amp;title=Psoriasis&amp;author=C.E.M.%20Griffiths&amp;author=A.W.%20Armstrong&amp;author=J.E.%20Gudjonsson&amp;author=J.%20Barker&amp;volume=397&amp;publication_year=2021&amp;pages=1301-1315&amp;pmid=33812489&amp;doi=10.1016\/S0140-6736(20)32549-6&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>3.Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945\u20131960. doi: 10.1001\/jama.2020.4006.\u00a0[<a href=\"https:\/\/doi.org\/10.1001\/jama.2020.4006\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32427307\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=JAMA&amp;title=Pathophysiology,%20Clinical%20Presentation,%20and%20Treatment%20of%20Psoriasis:%20A%20Review&amp;author=A.W.%20Armstrong&amp;author=C.%20Read&amp;volume=323&amp;publication_year=2020&amp;pages=1945-1960&amp;pmid=32427307&amp;doi=10.1001\/jama.2020.4006&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>4.Kaushik S.B., Lebwohl M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 2019;80:27\u201340. doi: 10.1016\/j.jaad.2018.06.057.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2018.06.057\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30017705\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Psoriasis:%20Which%20therapy%20for%20which%20patient:%20Psoriasis%20comorbidities%20and%20preferred%20systemic%20agents&amp;author=S.B.%20Kaushik&amp;author=M.G.%20Lebwohl&amp;volume=80&amp;publication_year=2019&amp;pages=27-40&amp;pmid=30017705&amp;doi=10.1016\/j.jaad.2018.06.057&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>5.Reid C., Griffiths C.E.M. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm.-Venereol. 2020;100:adv00032. doi: 10.2340\/00015555-3386.\u00a0[<a href=\"https:\/\/doi.org\/10.2340\/00015555-3386\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9128930\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31971601\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Acta%20Derm.-Venereol.&amp;title=Psoriasis%20and%20Treatment:%20Past,%20Present%20and%20Future%20Aspects&amp;author=C.%20Reid&amp;author=C.E.M.%20Griffiths&amp;volume=100&amp;publication_year=2020&amp;pages=adv00032&amp;pmid=31971601&amp;doi=10.2340\/00015555-3386&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>6.Singh A., Easwari T.S. Recent Advances in Psoriasis Therapy: Trends and Future Prospects. Curr. Drug Targets. 2021;22:1760\u20131771. doi: 10.2174\/1389450122666210118103455.\u00a0[<a href=\"https:\/\/doi.org\/10.2174\/1389450122666210118103455\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33461464\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Curr.%20Drug%20Targets&amp;title=Recent%20Advances%20in%20Psoriasis%20Therapy:%20Trends%20and%20Future%20Prospects&amp;author=A.%20Singh&amp;author=T.S.%20Easwari&amp;volume=22&amp;publication_year=2021&amp;pages=1760-1771&amp;pmid=33461464&amp;doi=10.2174\/1389450122666210118103455&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>7.Gyldenl\u00f8ve M., Alinaghi F., Zachariae C., Skov L., Egeberg A. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. Am. J. Clin. Dermatol. 2022;23:605\u2013613. doi: 10.1007\/s40257-022-00703-1.\u00a0[<a href=\"https:\/\/doi.org\/10.1007\/s40257-022-00703-1\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35737251\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Am.%20J.%20Clin.%20Dermatol.&amp;title=Combination%20Therapy%20with%20Apremilast%20and%20Biologics%20for%20Psoriasis:%20A%20Systematic%20Review&amp;author=M.%20Gyldenl%C3%B8ve&amp;author=F.%20Alinaghi&amp;author=C.%20Zachariae&amp;author=L.%20Skov&amp;author=A.%20Egeberg&amp;volume=23&amp;publication_year=2022&amp;pages=605-613&amp;pmid=35737251&amp;doi=10.1007\/s40257-022-00703-1&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>8.Hsieh T.S., Tsai T.F. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. Dermatol. Ther. 2023;13:891\u2013909. doi: 10.1007\/s13555-023-00903-5.\u00a0[<a href=\"https:\/\/doi.org\/10.1007\/s13555-023-00903-5\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10060456\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36943580\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Dermatol.%20Ther.&amp;title=Combination%20Therapy%20for%20Psoriasis%20with%20Methotrexate%20and%20Other%20Oral%20Disease-Modifying%20Antirheumatic%20Drugs:%20A%20Systematic%20Review&amp;author=T.S.%20Hsieh&amp;author=T.F.%20Tsai&amp;volume=13&amp;publication_year=2023&amp;pages=891-909&amp;pmid=36943580&amp;doi=10.1007\/s13555-023-00903-5&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>9.Pourani M.R., Abdollahimajd F., Zargari O., Shahidi Dadras M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J. Dermatol. Treat. 2022;33:1967\u20131974. doi: 10.1080\/09546634.2021.1966357.\u00a0[<a href=\"https:\/\/doi.org\/10.1080\/09546634.2021.1966357\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34369253\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Dermatol.%20Treat.&amp;title=Soluble%20biomarkers%20for%20diagnosis,%20monitoring,%20and%20therapeutic%20response%20assessment%20in%20psoriasis&amp;author=M.R.%20Pourani&amp;author=F.%20Abdollahimajd&amp;author=O.%20Zargari&amp;author=M.%20Shahidi%20Dadras&amp;volume=33&amp;publication_year=2022&amp;pages=1967-1974&amp;pmid=34369253&amp;doi=10.1080\/09546634.2021.1966357&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>10.Lwin S.M., Snowden J.A., Griffiths C.E.M. The promise and challenges of cell therapy for psoriasis. Br. J. Dermatol. 2021;185:887\u2013898. doi: 10.1111\/bjd.20517.\u00a0[<a href=\"https:\/\/doi.org\/10.1111\/bjd.20517\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34036569\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Br.%20J.%20Dermatol.&amp;title=The%20promise%20and%20challenges%20of%20cell%20therapy%20for%20psoriasis&amp;author=S.M.%20Lwin&amp;author=J.A.%20Snowden&amp;author=C.E.M.%20Griffiths&amp;volume=185&amp;publication_year=2021&amp;pages=887-898&amp;pmid=34036569&amp;doi=10.1111\/bjd.20517&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>11.Salgado-Boquete L., Carrascosa J.M., Llamas-Velasco M., Ruiz-Villaverde R., de la Cueva P., Belinch\u00f3n I. A New Classification of the Severity of Psoriasis: What\u2019s Moderate Psoriasis? Life. 2021;11:627. doi: 10.3390\/life11070627.\u00a0[<a href=\"https:\/\/doi.org\/10.3390\/life11070627\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8307918\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34209585\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Life&amp;title=A%20New%20Classification%20of%20the%20Severity%20of%20Psoriasis:%20What%E2%80%99s%20Moderate%20Psoriasis?&amp;author=L.%20Salgado-Boquete&amp;author=J.M.%20Carrascosa&amp;author=M.%20Llamas-Velasco&amp;author=R.%20Ruiz-Villaverde&amp;author=P.%20de%20la%20Cueva&amp;volume=11&amp;publication_year=2021&amp;pages=627&amp;pmid=34209585&amp;doi=10.3390\/life11070627&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>12.Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E., Nast A., Franke J., Antoniou C., Arenberger P., Balieva F., et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 2011;303:1\u201310. doi: 10.1007\/s00403-010-1080-1.\u00a0[<a href=\"https:\/\/doi.org\/10.1007\/s00403-010-1080-1\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3016217\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20857129\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Arch.%20Dermatol.%20Res.&amp;title=Definition%20of%20treatment%20goals%20for%20moderate%20to%20severe%20psoriasis:%20A%20European%20consensus&amp;author=U.%20Mrowietz&amp;author=K.%20Kragballe&amp;author=K.%20Reich&amp;author=P.%20Spuls&amp;author=C.E.%20Griffiths&amp;volume=303&amp;publication_year=2011&amp;pages=1-10&amp;pmid=20857129&amp;doi=10.1007\/s00403-010-1080-1&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>13.Oranje A.P., Marcoux D., Svensson A., Prendiville J., Krafchik B., Toole J., Rosenthal D., de Waard-van der Spek F.B., Molin L., Axelsen M. Topical calcipotriol in childhood psoriasis. J. Am. Acad. Dermatol. 1997;36:203\u2013208. doi: 10.1016\/S0190-9622(97)70281-0.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/S0190-9622(97)70281-0\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9039169\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Topical%20calcipotriol%20in%20childhood%20psoriasis&amp;author=A.P.%20Oranje&amp;author=D.%20Marcoux&amp;author=A.%20Svensson&amp;author=J.%20Prendiville&amp;author=B.%20Krafchik&amp;volume=36&amp;publication_year=1997&amp;pages=203-208&amp;pmid=9039169&amp;doi=10.1016\/S0190-9622(97)70281-0&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>14.Maul J.T., Anzengruber F., Conrad C., Cozzio A., H\u00e4usermann P., Jalili A., Kolios A.G.A., Laffitte E., Lapointe A.K., Mainetti C., et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237:166\u2013178. doi: 10.1159\/000512930.\u00a0[<a href=\"https:\/\/doi.org\/10.1159\/000512930\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33406520\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Dermatology&amp;title=Topical%20Treatment%20of%20Psoriasis%20Vulgaris:%20The%20Swiss%20Treatment%20Pathway&amp;author=J.T.%20Maul&amp;author=F.%20Anzengruber&amp;author=C.%20Conrad&amp;author=A.%20Cozzio&amp;author=P.%20H%C3%A4usermann&amp;volume=237&amp;publication_year=2021&amp;pages=166-178&amp;pmid=33406520&amp;doi=10.1159\/000512930&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>15.Elmets C.A., Korman N.J., Prater E.F., Wong E.B., Rupani R.N., Kivelevitch D., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R., et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J. Am. Acad. Dermatol. 2021;84:432\u2013470. doi: 10.1016\/j.jaad.2020.07.087.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2020.07.087\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32738429\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Joint%20AAD-NPF%20Guidelines%20of%20care%20for%20the%20management%20and%20treatment%20of%20psoriasis%20with%20topical%20therapy%20and%20alternative%20medicine%20modalities%20for%20psoriasis%20severity%20measures&amp;author=C.A.%20Elmets&amp;author=N.J.%20Korman&amp;author=E.F.%20Prater&amp;author=E.B.%20Wong&amp;author=R.N.%20Rupani&amp;volume=84&amp;publication_year=2021&amp;pages=432-470&amp;pmid=32738429&amp;doi=10.1016\/j.jaad.2020.07.087&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>16.Blauvelt A., Leonardi C.L., Gooderham M., Papp K.A., Philipp S., Wu J.J., Igarashi A., Flack M., Geng Z., Wu T., et al. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156:649\u2013658. doi: 10.1001\/jamadermatol.2020.0723.\u00a0[<a href=\"https:\/\/doi.org\/10.1001\/jamadermatol.2020.0723\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7142813\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32267471\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=JAMA%20Dermatol.&amp;title=Efficacy%20and%20Safety%20of%20Continuous%20Risankizumab%20Therapy%20vs%20Treatment%20Withdrawal%20in%20Patients%20With%20Moderate%20to%20Severe%20Plaque%20Psoriasis:%20A%20Phase%203%20Randomized%20Clinical%20Trial&amp;author=A.%20Blauvelt&amp;author=C.L.%20Leonardi&amp;author=M.%20Gooderham&amp;author=K.A.%20Papp&amp;author=S.%20Philipp&amp;volume=156&amp;publication_year=2020&amp;pages=649-658&amp;pmid=32267471&amp;doi=10.1001\/jamadermatol.2020.0723&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>17.Gold L.S., Lebwohl M.G., Sugarman J.L., Pariser D.M., Lin T., Martin G., Pillai R., Israel R., Ramakrishna T. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J. Am. Acad. Dermatol. 2018;79:287\u2013293. doi: 10.1016\/j.jaad.2018.03.040.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2018.03.040\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29614243\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Safety%20and%20efficacy%20of%20a%20fixed%20combination%20of%20halobetasol%20and%20tazarotene%20in%20the%20treatment%20of%20moderate-to-severe%20plaque%20psoriasis:%20Results%20of%202%20phase%203%20randomized%20controlled%20trials&amp;author=L.S.%20Gold&amp;author=M.G.%20Lebwohl&amp;author=J.L.%20Sugarman&amp;author=D.M.%20Pariser&amp;author=T.%20Lin&amp;volume=79&amp;publication_year=2018&amp;pages=287-293&amp;pmid=29614243&amp;doi=10.1016\/j.jaad.2018.03.040&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>18.Lis-\u015awi\u0119ty A., Fr\u0105tczak A. Proactive therapy: New perspectives for long-term topical treatment of psoriasis. Dermatol. Ther. 2022;35:e15364. doi: 10.1111\/dth.15364.\u00a0[<a href=\"https:\/\/doi.org\/10.1111\/dth.15364\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35133689\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Dermatol.%20Ther.&amp;title=Proactive%20therapy:%20New%20perspectives%20for%20long-term%20topical%20treatment%20of%20psoriasis&amp;author=A.%20Lis-%C5%9Awi%C4%99ty&amp;author=A.%20Fr%C4%85tczak&amp;volume=35&amp;publication_year=2022&amp;pages=e15364&amp;pmid=35133689&amp;doi=10.1111\/dth.15364&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>19.Soleymani T., Hung T., Soung J. The role of vitamin D in psoriasis: A review. Int. J. Dermatol. 2015;54:383\u2013392. doi: 10.1111\/ijd.12790.\u00a0[<a href=\"https:\/\/doi.org\/10.1111\/ijd.12790\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25601579\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Int.%20J.%20Dermatol.&amp;title=The%20role%20of%20vitamin%20D%20in%20psoriasis:%20A%20review&amp;author=T.%20Soleymani&amp;author=T.%20Hung&amp;author=J.%20Soung&amp;volume=54&amp;publication_year=2015&amp;pages=383-392&amp;pmid=25601579&amp;doi=10.1111\/ijd.12790&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>20.Amiri D., Schwarz C.W., Gether L., Skov L. Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review. Acta Derm.-Venereol. 2023;103:adv00890. doi: 10.2340\/actadv.v103.6525.\u00a0[<a href=\"https:\/\/doi.org\/10.2340\/actadv.v103.6525\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10026016\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36916954\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Acta%20Derm.-Venereol.&amp;title=Safety%20and%20Efficacy%20of%20Topical%20Calcineurin%20Inhibitors%20in%20the%20Treatment%20of%20Facial%20and%20Genital%20Psoriasis:%20A%20Systematic%20Review&amp;author=D.%20Amiri&amp;author=C.W.%20Schwarz&amp;author=L.%20Gether&amp;author=L.%20Skov&amp;volume=103&amp;publication_year=2023&amp;pages=adv00890&amp;pmid=36916954&amp;doi=10.2340\/actadv.v103.6525&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>21.Fritz K., Salavastru C. The 308\u2009nm Excimer laser for the treatment of psoriasis and inflammatory skin diseases. Der Hautarzt Z. Dermatol. Venerol. Verwandte Geb. 2018;69:35\u201343. doi: 10.1007\/s00105-017-4105-2.\u00a0[<a href=\"https:\/\/doi.org\/10.1007\/s00105-017-4105-2\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29299629\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Der%20Hautarzt%20Z.%20Dermatol.%20Venerol.%20Verwandte%20Geb.&amp;title=The%20308%E2%80%89nm%20Excimer%20laser%20for%20the%20treatment%20of%20psoriasis%20and%20inflammatory%20skin%20diseases&amp;author=K.%20Fritz&amp;author=C.%20Salavastru&amp;volume=69&amp;publication_year=2018&amp;pages=35-43&amp;pmid=29299629&amp;doi=10.1007\/s00105-017-4105-2&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>22.Menter A., Strober B.E., Kaplan D.H., Kivelevitch D., Prater E.F., Stoff B., Armstrong A.W., Connor C., Cordoro K.M., Davis D.M.R., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J. Am. Acad. Dermatol. 2019;80:1029\u20131072. doi: 10.1016\/j.jaad.2018.11.057.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30772098\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Joint%20AAD-NPF%20guidelines%20of%20care%20for%20the%20management%20and%20treatment%20of%20psoriasis%20with%20biologics&amp;author=A.%20Menter&amp;author=B.E.%20Strober&amp;author=D.H.%20Kaplan&amp;author=D.%20Kivelevitch&amp;author=E.F.%20Prater&amp;volume=80&amp;publication_year=2019&amp;pages=1029-1072&amp;pmid=30772098&amp;doi=10.1016\/j.jaad.2018.11.057&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>23.Menter A., Gelfand J.M., Connor C., Armstrong A.W., Cordoro K.M., Davis D.M.R., Elewski B.E., Gordon K.B., Gottlieb A.B., Kaplan D.H., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J. Am. Acad. Dermatol. 2020;82:1445\u20131486. doi: 10.1016\/j.jaad.2020.02.044.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2020.02.044\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32119894\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Joint%20American%20Academy%20of%20Dermatology-National%20Psoriasis%20Foundation%20guidelines%20of%20care%20for%20the%20management%20of%20psoriasis%20with%20systemic%20nonbiologic%20therapies&amp;author=A.%20Menter&amp;author=J.M.%20Gelfand&amp;author=C.%20Connor&amp;author=A.W.%20Armstrong&amp;author=K.M.%20Cordoro&amp;volume=82&amp;publication_year=2020&amp;pages=1445-1486&amp;pmid=32119894&amp;doi=10.1016\/j.jaad.2020.02.044&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>24.Elmets C.A., Lim H.W., Stoff B., Connor C., Cordoro K.M., Lebwohl M., Armstrong A.W., Davis D.M.R., Elewski B.E., Gelfand J.M., et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J. Am. Acad. Dermatol. 2019;81:775\u2013804. doi: 10.1016\/j.jaad.2019.04.042.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2019.04.042\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31351884\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Joint%20American%20Academy%20of%20Dermatology-National%20Psoriasis%20Foundation%20guidelines%20of%20care%20for%20the%20management%20and%20treatment%20of%20psoriasis%20with%20phototherapy&amp;author=C.A.%20Elmets&amp;author=H.W.%20Lim&amp;author=B.%20Stoff&amp;author=C.%20Connor&amp;author=K.M.%20Cordoro&amp;volume=81&amp;publication_year=2019&amp;pages=775-804&amp;pmid=31351884&amp;doi=10.1016\/j.jaad.2019.04.042&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>25.Lambert J.L.W., Segaert S., Ghislain P.D., Hillary T., Nikkels A., Willaert F., Lambert J., Speeckaert R. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1) J. Eur. Acad. Dermatol. Venereol. JEADV. 2020;34:1654\u20131665. doi: 10.1111\/jdv.16684.\u00a0[<a href=\"https:\/\/doi.org\/10.1111\/jdv.16684\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7496083\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32735076\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Eur.%20Acad.%20Dermatol.%20Venereol.%20JEADV&amp;title=Practical%20recommendations%20for%20systemic%20treatment%20in%20psoriasis%20according%20to%20age,%20pregnancy,%20metabolic%20syndrome,%20mental%20health,%20psoriasis%20subtype%20and%20treatment%20history%20(BETA-PSO:%20Belgian%20Evidence-based%20Treatment%20Advice%20in%20Psoriasis;%20part%201)&amp;author=J.L.W.%20Lambert&amp;author=S.%20Segaert&amp;author=P.D.%20Ghislain&amp;author=T.%20Hillary&amp;author=A.%20Nikkels&amp;volume=34&amp;publication_year=2020&amp;pages=1654-1665&amp;pmid=32735076&amp;doi=10.1111\/jdv.16684&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>26.Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156:258\u2013269. doi: 10.1001\/jamadermatol.2019.4029.\u00a0[<a href=\"https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7042876\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32022825\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=JAMA%20Dermatol.&amp;title=Comparison%20of%20Biologics%20and%20Oral%20Treatments%20for%20Plaque%20Psoriasis:%20A%20Meta-analysis&amp;author=A.W.%20Armstrong&amp;author=L.%20Puig&amp;author=A.%20Joshi&amp;author=M.%20Skup&amp;author=D.%20Williams&amp;volume=156&amp;publication_year=2020&amp;pages=258-269&amp;pmid=32022825&amp;doi=10.1001\/jamadermatol.2019.4029&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>27.Kimball A.B., Rothman K.J., Kricorian G., Pariser D., Yamauchi P.S., Menter A., Teller C.F., Aras G., Accortt N.A., Hooper M., et al. OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. J. Am. Acad. Dermatol. 2015;72:115\u2013122. doi: 10.1016\/j.jaad.2014.08.050.\u00a0[<a href=\"https:\/\/doi.org\/10.1016\/j.jaad.2014.08.050\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4758511\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25264239\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=OBSERVE-5:%20Observational%20postmarketing%20safety%20surveillance%20registry%20of%20etanercept%20for%20the%20treatment%20of%20psoriasis%20final%205-year%20results&amp;author=A.B.%20Kimball&amp;author=K.J.%20Rothman&amp;author=G.%20Kricorian&amp;author=D.%20Pariser&amp;author=P.S.%20Yamauchi&amp;volume=72&amp;publication_year=2015&amp;pages=115-122&amp;pmid=25264239&amp;doi=10.1016\/j.jaad.2014.08.050&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>28.Menter A., Tha\u00e7i D., Wu J.J., Abramovits W., Kerdel F., Arikan D., Guo D., Ganguli A., Bereswill M., Camez A., et al. Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. Dermatol. Ther. 2017;7:365\u2013381. doi: 10.1007\/s13555-017-0198-x.\u00a0[<a href=\"https:\/\/doi.org\/10.1007\/s13555-017-0198-x\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5574748\/\" target=\"_blank\" rel=\"noopener\">PMC free article<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28815476\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=Dermatol.%20Ther.&amp;title=Long-Term%20Safety%20and%20Effectiveness%20of%20Adalimumab%20for%20Moderate%20to%20Severe%20Psoriasis:%20Results%20from%207-Year%20Interim%20Analysis%20of%20the%20ESPRIT%20Registry&amp;author=A.%20Menter&amp;author=D.%20Tha%C3%A7i&amp;author=J.J.%20Wu&amp;author=W.%20Abramovits&amp;author=F.%20Kerdel&amp;volume=7&amp;publication_year=2017&amp;pages=365-381&amp;pmid=28815476&amp;doi=10.1007\/s13555-017-0198-x&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p>29.Kalb R.E., Fiorentino D.F., Lebwohl M.G., Toole J., Poulin Y., Cohen A.D., Goyal K., Fakharzadeh S., Calabro S., Chevrier M., et al. Risk of Serious Infection with Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR) JAMA Dermatol. 2015;151:961\u2013969. doi: 10.1001\/jamadermatol.2015.0718.\u00a0[<a href=\"https:\/\/doi.org\/10.1001\/jamadermatol.2015.0718\" target=\"_blank\" rel=\"noreferrer noopener\">DOI<\/a>] [<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25970800\/\" target=\"_blank\" rel=\"noopener\">PubMed<\/a>] [<a href=\"https:\/\/scholar.google.com\/scholar_lookup?journal=JAMA%20Dermatol.&amp;title=Risk%20of%20Serious%20Infection%20with%20Biologic%20and%20Systemic%20Treatment%20of%20Psoriasis:%20Results%20From%20the%20Psoriasis%20Longitudinal%20Assessment%20and%20Registry%20(PSOLAR)&amp;author=R.E.%20Kalb&amp;author=D.F.%20Fiorentino&amp;author=M.G.%20Lebwohl&amp;author=J.%20Toole&amp;author=Y.%20Poulin&amp;volume=151&amp;publication_year=2015&amp;pages=961-969&amp;pmid=25970800&amp;doi=10.1001\/jamadermatol.2015.0718&amp;\" target=\"_blank\" rel=\"noreferrer noopener\">Google Scholar<\/a>]<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>What\u2019s the Deal with My Psoriasis Treatment? Why Can\u2019t I Come Out of Psoriasis? Estimated Reading Time: 10 Minutes Psoriasis is a chronic autoimmune skin condition that manifests in several forms, each with varying severity and requiring individualized treatment (Langley, Krueger, &amp; Griffiths, 2005; Parisi et al., 2013). Its unpredictable nature, coupled with the inadequacies [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"post-5040","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-uncategorized"},"_links":{"self":[{"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/posts\/5040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/comments?post=5040"}],"version-history":[{"count":1,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/posts\/5040\/revisions"}],"predecessor-version":[{"id":5044,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/posts\/5040\/revisions\/5044"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/media\/5043"}],"wp:attachment":[{"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/media?parent=5040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/categories?post=5040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eliteayurveda.com\/blog\/wp-json\/wp\/v2\/tags?post=5040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}